Abstract 607: Genomic analyses and novel models validate CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans
Adrián Mariño‐Enríquez(Harvard University Press), Jonathan A. Fletcher(Harvard University), Ewa Sicińska(Harvard University), Mei‐Jun Zhu(Washington State University), Andrew J. Wagner(Dana-Farber Cancer Institute), Jason L. Hornick(Harvard University), Grant Eilers(Brigham and Women's Hospital), Mark Mayeda(Brigham and Women's Hospital), Derrick L. Tao(Brigham and Women's Hospital), Jeffrey T. Czaplinski(Harvard University)
Cited by 0
Related Papers
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
|Oncogene|2001|700
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
|American Journal Of Pathology|2000|647
Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma
|American Journal Of Pathology|2001|639